People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Other Technology, Pharmaceuticals, Other Health Care, Other, Manufacturing, Climate / Cleantech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viasat Inc | — | Other Technology | Series D+ | $312.8M | $5.5B | 2020 |
| Phlow Corp. | — | Pharmaceuticals | Series B | $82.8M | $169.3M | 2024 |
| Nirvanix, Inc. | — | Other Technology | Series B | $30.6M | $463.3M | 2010 |
| Medicrea | — | Other Health Care | Series B | $22.0M | $487.4M | 2016 |
| Access Sports Media Inc. | — | Other | Series A | $20.5M | $22.7M | 2010 |
| Albeo Technologies Inc | — | Manufacturing | Series A | $7.9M | $64.9M | 2009 |
| International Battery Metals Ltd. | — | Climate / Cleantech | Seed | $3.1M | $918K | 2019 |
| Insuraguest Technologies Inc. | — | Software / Tech | Pre-Seed | $614K | $7.4M | 2020 |
| Workwell Systems Inc | — | Other Health Care | Pre-Seed | $507K | $15.6M | 2009 |
David Ryan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Ryan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Logan Anderson | 2 | 3 |
| Mark Miller | 1 | 18 |
| DAVID WEIDEN | 1 | 13 |
| David Scott | 1 | 12 |
| Robert Johnson | 1 | 9 |
| David Levin | 1 | 7 |
| Dennis Costello | 1 | 6 |
| Robert Blair | 1 | 6 |
| Sean O'Neill | 1 | 5 |
| Lon Otremba | 1 | 5 |
| Charles Curran | 1 | 4 |
| Christopher W. Nelson | 1 | 3 |
| Jay Stead | 1 | 3 |
| Jeffrey Patterson | 1 | 3 |
| Richard Kienzle | 1 | 3 |
| Harvey White | 1 | 3 |
| Michael Wall | 1 | 3 |
| Eric Edwards | 1 | 3 |
| Jeff Patterson | 1 | 2 |
| David J. Ryan | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.